Ipilimumab vs Tofacitinib
Ipilimumab vs Tofacitinib: Overview
This comparison examines the pharmacological differences between Ipilimumab and Tofacitinib.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Tofacitinib — 3.2 hours.
Chemical Properties
Molecular Formula: Tofacitinib — C16H20N6O.
Molecular Weight: Tofacitinib — 312.3700 g/mol.
Type: Ipilimumab — Antibody; Tofacitinib — Small molecule.